Investigating genetics in patients with severe depression treated with ECT
2/2 Genetics at an extreme: an efficient genomic study of individuals with clinically severe major depression receiving ECT
This study is looking at how genes might affect how well people with severe depression respond to electroconvulsive therapy (ECT), so we can better identify who will benefit from this treatment and make it easier for them to find the right help.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-10674837 on NIH RePORTER |
What this research studies
This research focuses on understanding the genetic factors associated with severe major depressive disorder (MDD) in individuals receiving electroconvulsive therapy (ECT). By analyzing genetic variations, the study aims to identify which patients are most likely to benefit from ECT and how their genetic makeup influences treatment response. This could help streamline treatment options for patients suffering from severe depression, reducing the trial-and-error approach often required to find effective therapies. The research involves collaboration among global experts to enhance the understanding of this complex mental health condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with severe major depressive disorder who are undergoing electroconvulsive therapy.
Not a fit: Patients with mild depression or those not receiving ECT may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatment options for patients with severe depression.
How similar studies have performed: Previous genetic studies have shown promise in identifying susceptibility loci for depression, indicating that this approach has potential for success.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Sullivan, Patrick F — Univ of North Carolina Chapel Hill
- Study coordinator: Sullivan, Patrick F
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.